Invasive fungal infections (IFIs) are often found in critical care settings. Patients with compromised immune systems or multiple comorbidities make these infections a real challenge in clinical practice. The most common fungal pathogens are Aspergillus and Candida. On the other hand, we know that patients’ susceptibility for bacterial and fungal superinfections increases in viraemic pneumonia infections and reports have shown that during the COVID-19 pandemic, these infections have been considered an additional contributing factor to patients’ mortality.
In this webinar, we will evaluate these new risk factors for the IFIs and analyse the behaviour of these organisms in a post-COVID intensive care unit.
- Review of current insights and knowledge gaps in the definitions, epidemiology, diagnosis, and management of CAPA.
- Candida infections in critically ill patients and their related resistance.
- Outcome of the patients with resistant Candida infection.
Topics and Experts:
“COVID-19 associated pulmonary aspergillosis (CAPA)”
Dr Anahita ROUZÉ
Pôle de Médecine intensive – Réanimation, Hôpital R. Salengro, CHRU de Lille (FR)
“Candida resistance in the critical ill: what impact on the outcome?”
Prof José Artur PAIVA
Director of Intensive Care Department Centro Hospitalar Universitário São João, Porto (PT)
Dr Laura GALARZA
Chair-Elect, ESICM NEXT Committee
Thanks to the support of